- Home
- NXE vs OGN Comparison
NXE vs OGN Comparison
Compare NXE & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXE
- OGN
- Stock Information
- Founded
- NXE N/A
- OGN 1923
- Country
- NXE Canada
- OGN United States
- Employees
- NXE N/A
- OGN N/A
- Industry
- NXE
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- NXE
- OGN Health Care
- Exchange
- NXE Nasdaq
- OGN Nasdaq
- Market Cap
- NXE 4.3B
- OGN 4.0B
- IPO Year
- NXE N/A
- OGN N/A
- Fundamental
- Price
- NXE $7.38
- OGN $14.98
- Analyst Decision
- NXE
- OGN Hold
- Analyst Count
- NXE 0
- OGN 3
- Target Price
- NXE N/A
- OGN $21.33
- AVG Volume (30 Days)
- NXE 6.6M
- OGN 2.9M
- Earning Date
- NXE 11-08-2024
- OGN 02-13-2025
- Dividend Yield
- NXE N/A
- OGN 7.65%
- EPS Growth
- NXE N/A
- OGN 120.97
- EPS
- NXE 0.20
- OGN 5.04
- Revenue
- NXE N/A
- OGN $6,409,000,000.00
- Revenue This Year
- NXE N/A
- OGN $3.11
- Revenue Next Year
- NXE N/A
- OGN $2.55
- P/E Ratio
- NXE $38.19
- OGN $2.93
- Revenue Growth
- NXE N/A
- OGN 4.21
- 52 Week Low
- NXE $4.95
- OGN $13.14
- 52 Week High
- NXE $8.96
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- NXE 38.37
- OGN 42.91
- Support Level
- NXE $7.09
- OGN $14.53
- Resistance Level
- NXE $8.14
- OGN $15.41
- Average True Range (ATR)
- NXE 0.31
- OGN 0.52
- MACD
- NXE -0.15
- OGN 0.02
- Stochastic Oscillator
- NXE 13.61
- OGN 31.89
About NXE Nexgen Energy Ltd.
NexGen Energy Ltd is a mineral exploration company. It is engaged in the acquisition, exploration, evaluation and development of uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin. The Rook I property hosts the world-class Arrow Zone, the Bow discovery. as well as the discovered Harpoon area located northeast of the Arrow deposit.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.